CAM
CLDX icon

Cormorant Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Cormorant Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200,000
Closed -$5.39M – 77
2022
Q2 		$5.39M Buy
+200,000
New +$5.81M 0.41% 51
2022
Q1 		– Sell
-100,000
Closed -$3.86M – 80
2021
Q4 		$3.86M Buy
+100,000
New +$4.36M 0.23% 59

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Cormorant Asset Management's CLDX Position: Q3 2022 in Review

Cormorant Asset Management sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 200,000 shares — an estimated $5.39M sold.

Cormorant Asset Management first reported a position in CLDX in Q4 2021 and held it in 2 quarters. The position peaked at $5.39M in Q2 2022. 159 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

  • Cormorant Asset Management reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cormorant Asset Management sold 200,000 Celldex Therapeutics shares in Q3 2022, an estimated $5.39M.
  • Cormorant Asset Management first reported a position in Celldex Therapeutics in Q4 2021 and held it in 2 quarters.
  • Cormorant Asset Management's Celldex Therapeutics position peaked at $5.39M in Q2 2022.
  • 159 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Cormorant Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.